KRT18 and neoplasm: With regard to tumor cell proliferation under the 2 treatment strategies, this was reduced by nivolumab, as obvious from reduction of EdU staining in positive CK18 tumor cells in both patients, while combination therapy reduced the proliferation rate of tumor cells in only one patient (Figure 5B).